Zacks: Brokerages Anticipate Natus Medical Inc (BABY) Will Post Quarterly Sales of $136.64 Million

Share on StockTwits

Brokerages expect that Natus Medical Inc (NASDAQ:BABY) will post sales of $136.64 million for the current quarter, according to Zacks. Three analysts have issued estimates for Natus Medical’s earnings. The highest sales estimate is $137.32 million and the lowest is $136.00 million. Natus Medical reported sales of $131.44 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 4%. The company is expected to announce its next earnings results on Wednesday, February 6th.

On average, analysts expect that Natus Medical will report full-year sales of $526.54 million for the current financial year, with estimates ranging from $525.90 million to $527.22 million. For the next year, analysts forecast that the business will report sales of $541.60 million, with estimates ranging from $535.00 million to $553.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Natus Medical.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.02). The company had revenue of $130.60 million for the quarter, compared to the consensus estimate of $132.92 million. Natus Medical had a negative net margin of 3.53% and a positive return on equity of 11.34%. The firm’s revenue was up 6.5% compared to the same quarter last year. During the same period last year, the business posted $0.40 EPS.

Several brokerages have issued reports on BABY. Roth Capital set a $36.00 target price on Natus Medical and gave the company a “buy” rating in a research report on Thursday, October 25th. Zacks Investment Research cut Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, October 26th. BidaskClub raised Natus Medical from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, ValuEngine raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Natus Medical currently has a consensus rating of “Hold” and an average price target of $42.50.

NASDAQ BABY traded up $1.38 during midday trading on Thursday, hitting $31.26. 301,527 shares of the company traded hands, compared to its average volume of 348,109. The company has a current ratio of 3.21, a quick ratio of 2.31 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.01 billion, a PE ratio of 21.56 and a beta of 0.59. Natus Medical has a 52 week low of $27.69 and a 52 week high of $43.60.

In other Natus Medical news, insider Jonathan Kennedy sold 47,600 shares of the stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $36.85, for a total transaction of $1,754,060.00. Following the sale, the insider now owns 161,628 shares of the company’s stock, valued at approximately $5,955,991.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. WCM Investment Management CA boosted its position in shares of Natus Medical by 23.0% in the 3rd quarter. WCM Investment Management CA now owns 215,894 shares of the medical equipment provider’s stock worth $7,697,000 after purchasing an additional 40,344 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Natus Medical by 9.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 27,104 shares of the medical equipment provider’s stock worth $966,000 after purchasing an additional 2,441 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Natus Medical by 117.6% in the 3rd quarter. First Trust Advisors LP now owns 49,756 shares of the medical equipment provider’s stock worth $1,774,000 after purchasing an additional 26,892 shares in the last quarter. Fenimore Asset Management Inc. boosted its position in shares of Natus Medical by 20.2% in the 3rd quarter. Fenimore Asset Management Inc. now owns 392,145 shares of the medical equipment provider’s stock worth $13,980,000 after purchasing an additional 65,795 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Natus Medical by 29.8% in the 3rd quarter. Bank of Montreal Can now owns 55,651 shares of the medical equipment provider’s stock worth $1,984,000 after purchasing an additional 12,765 shares in the last quarter. 96.07% of the stock is owned by hedge funds and other institutional investors.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: Balance Sheet

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply